Compound repurposing
Small molecule compounds are being studied for repurposing in COVID-19 treament and research. Multiple small molecules that are approved to treat other disorders have shown potential effects on key proteins involved in SARS-CoV-2 host cell entry and replication. Repurposing of existing compounds is advantageous for speed - reducing timescales compared to conventional drug discovery. Researchers can save up to 50% on these small molecules for COVID-19 research, as they are up to half the price of other suppliers.
Malformin C (HB3966)
Description:Antibiotic. Potent G2 checkpoint cell cycle arrest inhibitor
Purity:>95%
Minocycline hydrochloride (HB4617)
Description:Broad spectrum antibiotic. Potent microglial activation inhibitor. Allows formation of EPSs.
Purity:>98%
Monensin sodium salt (HB4882)
Description:Protein transport inhibitor. Commonly used in cytokine staining.
Purity:>98%
Naphthomycin B (HB3988)
Description:Ansamycin antibiotic with antibacterial and antifungal activity
Purity:>98%